Advertisement
Finance
Subscribe to Finance

The Lead

US Health Care Unprepared for Ebola

October 29, 2014 2:00 pm | by JEFF DONN, Associated Press; GARANCE BURKE, Associated Press | News | Comments

The U.S. health care apparatus is so unprepared and short on resources to deal with the deadly Ebola virus that even small clusters of cases could overwhelm parts of the system, according to an Associated Press review of readiness at hospitals and other components of the emergency medical network.

Vertex' Losses Less Than Wall Street Third Quarter Forecasts

October 29, 2014 8:29 am | News | Comments

Vertex Pharmaceuticals on Tuesday reported a loss of $170.1 million in its third quarter. On a...

States Ask Congress to Intervene on Drug Prices

October 29, 2014 8:24 am | News | Comments

In a letter Tuesday to key congressional committees, the National Association of Medicaid...

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance

October 29, 2014 8:19 am | News | Comments

In a move that will strengthen their alliance by enhancing efficiencies and enabling greater...

View Sample

FREE Email Newsletter

Amgen Beats Third Quarter Estimates While Shrinking Workforce

October 28, 2014 8:31 am | by MATTHEW PERRONE, AP Business Writer | News | Comments

Amgen said Monday that its earnings fell in the third quarter on charges from an ongoing restructuring effort, but the biotech drugmaker's adjusted results still surpassed Wall Street expectations.         

Sanofi Shares Plunge Due to Diabetes Drug Pricing Pressures

October 28, 2014 8:20 am | News | Comments

Sanofi saw its stock price plunge today after it reported a slide in quarterly earnings and warned of pricing pressure on its blockbuster diabetes treatment in the U.S. Sanofi shares fell 8.4 percent to 76.39 euros, forfeiting gains in the run-up to the announcement.

Pfizer Beats Wall Street Third Quarter Forecasts

October 28, 2014 8:13 am | News | Comments

On a per-share basis, the New York-based company said it had profit of 42 cents. Earnings, adjusted for non-recurring costs and to account for discontinued operations, were 57 cents per share.          

Advertisement

Novartis Posts Strong Profit

October 28, 2014 7:35 am | by The Associated Press | News | Comments

Novartis AG has posted a 45 percent rise in net profit in the third quarter, boosted by strong sales of new products such as Gilenya for multiple sclerosis and the leukemia drug Tasigna. The Basel, Switzerland-based company's reported quarterly net profit was $3.24B

GlaxoSmithKline Third Quarter 2014 Results Interview with CEO Sir Andrew Witty & CFO Simon Dingemans.

October 27, 2014 9:07 am | Videos | Comments

Interview with Sir Andrew Witty, CEO, and Simon Dingemans, CFO announcing the company's Q3 2014 results including a restructuring of the business and a possible partial IPO of ViiV Healthcare.          

Fujifilm to Buy U.S. Vaccine Maker to Expand Biopharma Business

October 27, 2014 8:56 am | News | Comments

Fujifilm will acquire U.S. vaccine maker Kalon Biotherapeutics to expand its biopharmaceutical business, with the Japanese firm having gained prominence for offering a possible treatment for Ebola patients.        

CSL to Acquire Novartis' Influenza Vaccine Business

October 27, 2014 8:43 am | News | Comments

CSL Limited today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.            

Merck's Third Quarter Net Income Falls But Profits Top Analysts' Estimates

October 27, 2014 8:31 am | News | Comments

Merck's third-quarter net income fell mostly because of large costs tied to acquisitions and divestitures. But the company's adjusted earnings topped Wall Street's view, and it narrowed its full-year adjusted earnings forecast on Monday.  

Advertisement

Zogenix Acquires U.K.-Based Brabant Pharma

October 27, 2014 8:24 am | News | Comments

Zogenix, Inc. today announced that it acquired Brabant Pharma, a privately-held U.K.-based pharmaceutical company for $20 million in cash and $15 million in stock plus potential future milestone and royalty payments.      

Valeant: We'll Bump Allergan Offer to $200 a Share

October 27, 2014 7:33 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International says it will raise its offer for Botox maker Allergan to $200 or more per share. Valeant made the statement in a letter to Allergan's board released publicly seeking to urge Allergan to talk about an acquisition.

Drugmakers Bet on Ebola Vaccines, Treatments

October 26, 2014 9:33 am | by Matthew Perrone - Associated Press - Associated Press | News | Comments

Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history. It's unclear who will pay for their products, but companies are betting that governments and aid groups will foot the bill.    

Bristol-Myers Squibb Tops Wall Street Third Quarter Forecasts

October 24, 2014 8:39 am | by The Associated Press | News | Comments

Bristol-Myers Squibb reported third-quarter profit of $721 million. The New York-based company said it had profit of 43 cents per share. Earnings, adjusted for non-recurring costs, came to 45 cents per share. The results beat Wall Street expectations.

Pfizer Approves $11B Stock Repurchase Plan

October 23, 2014 4:38 pm | by The Associated Press | News | Comments

Pfizer says it approved the repurchase of $11 billion in company stock. The company did not say when it would buy back the shares. Pfizer has $1.3 billion remaining from its latest stock repurchase program.        

Advertisement

Patent Expirations Hit Eli Lilly Third Quarter Profit

October 23, 2014 1:43 pm | News | Comments

Eli Lilly said that its net income and sales sank in the third quarter after its antidepressant Cymbalta lost patent protection and faced competition from less-expensive generics. Lilly said its revenue from Cymbalta plunged 73%t and revenue from the osteoporosis treatment Evista fell 65%.

Soliris Sales Boost Alexion's Third Quarter Results

October 23, 2014 1:21 pm | News | Comments

The company reported net product sales of Soliris® (eculizumab) of $555.1 million in the third quarter of 2014, an increase of 39 percent from the same period in 2013.              

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

October 23, 2014 10:31 am | News | Comments

The scope of the collaboration allows the parties to systematically interrogate the immuno-oncology space, including established targets, using Sutro’s cell-free biologics development platforms. During the collaboration, after an initial period, Celgene will have the exclusive option to acquire Sutro, including rights to all Sutro-owned programs at that time, on pre-specified terms.

GlobalData Analyst: Pharmaceutical Industry Feeling Force of Tax Inversion Legislation

October 23, 2014 9:30 am | News | Comments

The recent termination of AbbVie’s deal to acquire Shire makes this pharmaceuticals’ first major casualty of new US tax inversion legislation, and has jolted the industry out of its reverie, according to an analyst with research and consulting firm GlobalData.

Eli Lilly Adds $375M to Zymeworks Partnership

October 22, 2014 5:37 pm | by The Associated Press | News | Comments

The companies announced a team-up in January but did not disclose terms. Without explaining the initial terms of the partnership, the companies said Zymeworks could get an additional $375M in milestones and other payments.     

Biogen Idec Shares Slides as MS Drug is Linked to Inflammation

October 22, 2014 1:40 pm | News | Comments

The company confirmed there was a case of progressive multifocal leukoencephalopathy, or PML, in one patient who took the drug Tecfidera. It said the patient recently died of complications of pneumonia.         

Biogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5B

October 22, 2014 10:53 am | News | Comments

Biogen Idec has reported third quarter 2014 results, including revenue of $2.5B, a 37% increase compared to the third quarter of 2013. Third quarter 2014 non-GAAP diluted earnings per share (EPS) were $3.80, an increase of 61% over the third quarter of 2013. Non-GAAP net income attributable to Biogen Idec for the third quarter was $900M, an increase of 60% over the third quarter of 2013.

GlobalData Analyst: Harvoni Will Keep Gilead Atop Hepatitis C Virus Treatment Landscape

October 22, 2014 10:43 am | News | Comments

The recent FDA approval of Harvoni, Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus genotype 1 infection in adults, will enable the company to maintain its dominance in an increasingly competitive market, says an analyst with research and consulting firm GlobalData.

Roche Announces Plans for Future Investments at its Basel Site

October 22, 2014 8:46 am | News | Comments

Over the next 10 years, Roche will invest 3 billion Swiss francs in the construction of a new research and development centre for around 1,900 employees, in a state-of-the-art office building for up to 1,700 employees, in upgrading infrastructure, and in renovating the historic office building designed by Otto R. Salvisberg.

Hedge Fund Third Point Urges Amgen to Consider Breakup

October 22, 2014 8:24 am | by The Associated Press | News | Comments

A hedge fund run by a famed investor has taken a large stake in Amgen and now wants the biotech drugmaker to consider splitting up into two. In a letter to investors, Third Point, a hedge fund run by Daniel Loeb, said it has recently increased its stake by an unspecified amount, making it one of the drugmaker's top shareholders.

German Firm Wins Appeal in Spain Thalidomide Case

October 22, 2014 8:13 am | News | Comments

A Spanish court has upheld an appeal by a German pharmaceutical company, ditching a previous ruling that ordered the company to pay compensation to 22 Spaniards who blame their disabilities on the drug thalidomide.      

J&J to Spend Up to $200M on Ebola Vaccine Program

October 22, 2014 8:09 am | News | Comments

Johnson & Johnson will start safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus. The company has committed up to $200M to speed up and expand production of a vaccine program being developed by its Janssen Pharmaceutical Companies.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading